

# Comet Assay Case Study Interpretation Problem

Marie Z. Vasquez
Helix3 Inc.



## Compound X Ames Assay

- No statistically significant increases in revertant numbers
- No dose related increase
- Within HCD range
- Dosed up to solubility limit

Strain	<b>S9</b>	VC	Dose 1	Dose 2	Dose 3	Dose 4	Dose 5	PC
TA1535	-	11.2	14.6	11	9	12.2	10 <sup>∓</sup>	569
TA1537	-	10.6	4.6	13	11	9	3.2 <sup>∓</sup>	142.6
TA98	-	28	31.6	27	28	33.6	23.6 <sup>∓</sup>	89.6
TA100	-	161	156.2	147.2	139	133.6	139 <sup>∓</sup>	574.6
WP2 uvrA	-	48	46	49	49.6	44.2	41.6 <sup>∓</sup>	962.2
TA1535	+	9	9.2	11	12	10.2 <sup>‡</sup>	7.2 <sup>∓</sup>	105
TA1537	+	7	7.2	8	12.6	7.2 <sup>∓</sup>	7.6 <sup>∓</sup>	192.2
TA98	+	28.2	31.6	37.2	26	31.6 <sup>∓</sup>	29 <sup>∓</sup>	704.2
TA100	+	179.2	155.2	155.6	164.2	165.2 <sup>∓</sup>	159.2 <sup>∓</sup>	2006.2
WP2 uvrA	+	60	51.6	64	50.6	67.2	61 <sup>∓</sup>	145.6

<sup>&</sup>lt;sup>∓</sup> Precipitation



# Compound X Mouse Lymphoma Assay

- Statistically significant increase in mutation frequency at highest dose 3hr +S9
- Dose related increase
- Outside of HCD range
- Dosed up to cytotoxic dose
- No increase detected in repeat study

Dose	RTG % of VC	Mutant frequency x10 <sup>-6</sup>	Mean small colony mutant frequency x10 <sup>-6</sup>
VC		128	29
1	76.4	152	28
2	75.5	146	19
3	58.3	144	30
4	39.8	188	41
5	33.8	183	35
6	24.3	265*	71*
7	12.8 <sup>∓</sup>		
PC	38.8	1197*	261*

<sup>\*</sup>Mutant frequency > VC + Global eval factor

<sup>&</sup>lt;sup>†</sup> invalid dose due to low Relative total growth



### Compound X In Vivo PBL MN Assay


- Statistically significant increases in MN-PCEs at all doses
- No dose related increase
- All values within HCD range and below HCD mean value
- Dosed up to MFD with detected plasma concentrations

Dose	%PCEs	% MN-PCEs
VC	2.13	0.09
1	2.14	0.12*
2	2.35	0.13*
3	2.22	0.14*
PC	0.74*	1.94*

<sup>\*</sup>Statistically significant at p<0.001




# Compound X In Vivo Liver Comet Assay





- Statistically significant increases in %Tail
- Dose related increase
- All values within HCD range
- Dosed up to MTD with detected plasma concentrations
- Dosed and processed in order of dose



- No statistically significant increases in %Tail
- No dose related increase
- All values within HCD range
- Dosed up to MTD with higher plasma concentrations
- Dosed and processed in rotating order or block design





### What is the conclusion?





# Compound Y In Vivo Stomach Comet Assay





### Genetox profile

- Ames negative
- In vitro Chrom Ab positive but only at high dose with ppt
- In vivo BMMN negative



### Notes

"One complication with %Tail DNA is that the presence of zero values would complicate statistical analysis...There are suggestions that negative control cells should have between 10 and 20% DNA in [the] tail which would obviate statistical problems."

Lovell, David P., and Takashi Omori. (2008) Statistical Issues in the use of the comet assay. Mutagenesis Vol 23 (3) 171-182

"The best test of whether cells are in a satisfactory condition for comet assay analysis is that control, untreated cells should give comets with a background level of breaks (i.e., mostly class 0 [for visually scored cells] or ~10% of DNA in the tail [for image analysis scored cells]."

Collins, Andrew (2004) The comet assay for DNA damage and repair. Molecular Biotechnology Vol 26: 249-257